FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Heidelberg, Germany, March 23, 2017 - Affimed N.V. (Nasdaq: AFMD) today announced that on March 30, 2017, the Company will release its financial results for the quarter and year ended December 31, 2016. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Thursday, March 30, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 9811704.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 721 9158 |
| Local - Copenhagen, Denmark: | +45 32 71 16 60 |
| Local - Frankfurt, Germany: | +49 (0) 69 2222 10626 |
| Local - Geneva, Switzerland: | +41 (0) 22 417 7109 |
| Local - London, U.K.: | +44 (0) 20 3427 1911 |
| Local - New York City, U.S.A.: | +1 646 254 3361 |
| Local - Paris, France: | +33 (0) 1 76 77 22 22 |
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
